← Back to Search

Protein Phosphatase 2A Inhibitor

LB-100 for Glioblastoma

Phase 2
Waitlist Available
Led By Eric C Burton, M.D.
Research Sponsored by National Cancer Institute (NCI)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up pre-dose; end of infusion (2 hours post-start); 30 minutes post lb100 infusion completion; 1 hour post lb-100 infusion completion; 2 hours post lb100 infusion completion; 4 hours post lb100 infusion completion; 8 hours post lb100 infusion completion
Awards & highlights

Study Summary

This trial is testing if a new drug, LB100, can pass into the brain. People with brain tumors who are scheduled for surgery are eligible. The trial involves getting the drug during surgery and having follow-up appointments.

Eligible Conditions
  • Glioblastoma
  • Astrocytoma
  • Oligodendroglioma
  • Brain Tumor

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~pre-dose; end of infusion (2 hours post-start); 30 minutes post lb100 infusion completion; 1 hour post lb-100 infusion completion; 2 hours post lb100 infusion completion; 4 hours post lb100 infusion completion; 8 hours post lb100 infusion completion
This trial's timeline: 3 weeks for screening, Varies for treatment, and pre-dose; end of infusion (2 hours post-start); 30 minutes post lb100 infusion completion; 1 hour post lb-100 infusion completion; 2 hours post lb100 infusion completion; 4 hours post lb100 infusion completion; 8 hours post lb100 infusion completion for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of Participants With the Presence of Drug in the Tumor Tissue
Secondary outcome measures
Area Under the Plasma Concentration vs. Time Curve Extrapolated to Infinity (AUC(INF)
Brain Concentration
Brain Penetration
+8 more
Other outcome measures
Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)

Side effects data

From 2022 Phase 2 trial • 7 Patients • NCT03027388
71%
Headache
43%
Hypophosphatemia
29%
Agitation
29%
Hypomagnesemia
29%
Hiccups
14%
Facial muscle weakness
14%
Ear pain
14%
Hypocalcemia
14%
Muscle weakness left-sided
14%
Platelet count decreased
14%
Skin induration
14%
Nausea
14%
Myalgia
14%
Back pain
14%
Dysphasia
14%
Fever
14%
Ear and labyrinth disorders - Other, impacted cerumen
14%
Generalized muscle weakness
100%
80%
60%
40%
20%
0%
Study treatment Arm
1/LB100 Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma

Trial Design

1Treatment groups
Experimental Treatment
Group I: 1/LB100 Protein Phosphatase 2A Inhibitor, in Recurrent GlioblastomaExperimental Treatment1 Intervention
Treatment with LB100
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
LB-100
2019
Completed Phase 2
~10

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)Lead Sponsor
13,609 Previous Clinical Trials
40,915,639 Total Patients Enrolled
314 Trials studying Glioblastoma
22,439 Patients Enrolled for Glioblastoma
Eric C Burton, M.D.Principal InvestigatorNational Cancer Institute (NCI)

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are we still able to enroll people in this test?

"That is correct. The clinical trial in question, which was first advertised on 1/9/2019, is still looking for enrollees. So far, 25 patients have been recruited from a single site."

Answered by AI

What is the mortality rate for people who use LB-100?

"Since this is a Phase 2 trial, there is some data supporting LB-100's safety but none yet for its efficacy. Therefore, we gave it a score of 2."

Answered by AI

Are there similar precedents for LB-100's use?

"Currently, there are two clinical trials underway for LB-100; neither of which have reached Phase 3. Although the majority of testing for this treatment is taking place in Duarte, California - as that is where the company headquarters are located - there are two other research sites."

Answered by AI

How many patients are enrolled in this research project?

"That is correct. The clinical trial, which began recruitment on 1/9/2019, is still looking for 25 individuals from a single site."

Answered by AI
~1 spots leftby Mar 2025